Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMP6BSH)

• Drug Name: Orotic acid Drug Info
• Synonyms: 65-86-1; 6-Carboxyuracil; Oropur; Orodin; Orotonin; Orotonsan; Oroturic; Orotyl; Whey factor; Vitamin B13; 2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid; Uracil-6-carboxylic acid; 6-Uracilcarboxylic acid; Animal galactose factor; Orotsaeure; Molkensaeure; Uracil-6-carbosaeure; 4-Pyrimidinecarboxylic acid, 1,2,3,6-tetrahydro-2,6-dioxo-; 2,6-Dihydroxypyrimidine-4-carboxylic acid; 2,6-Dihydroxy-4-pyrimidinecarboxylic acid; Orotsaeure [German]; Acidum oroticum; Acide orotique; Acido orotico; Acidum oroti

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 967
  ChEBI ID: CHEBI:16742
  CAS Number: CAS 65-86-1
  TTD Drug ID: DMP6BSH

Molecule-Related Drug Atlas

Drug(s) Targeting Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Artemisinin	DMOY7W3	Malaria	1F40-1F45	Approved	[5]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[6]
Teriflunomide	DMQ2FKJ	Hyperlipidaemia	5C80	Approved	[7]
Atovaquone	DMY4UMW	Fungal infection	1F29-1F2F	Approved	[8]
Avastin+/-Tarceva	DMA86FL	Non-small-cell lung cancer	2C25.Y	Phase 3	[9]
Acetate Ion	DMD08RH	Discovery agent	N.A.	Investigative	[10]
B-Octylglucoside	DMMO75G	Discovery agent	N.A.	Investigative	[10]
Orotate	DMMB29S	Discovery agent	N.A.	Investigative	[11]
Lauryl Dimethylamine-N-Oxide	DM3W2OE	Discovery agent	N.A.	Investigative	[10]
1,4-Naphthoquinone	DMTCMH7	Discovery agent	N.A.	Investigative	[9]

Drug(s) Affected By Ribosomal protein S6 kinase beta-1 (RPS6KB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[12]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[13]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[14]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[15]
Trametinib	DM2JGQ3	Melanoma	2C30	Approved	[16]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[17]
Romiplostim	DM3U7SZ	Thrombocytopenia	3B64	Approved	[18]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[19]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[20]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[21]

Drug(s) Affected By Regulatory-associated protein of mTOR (RPTOR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[22]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[23]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[24]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[25]
Pioglitazone	DMKJ485	Amyotrophic lateral sclerosis	8B60.0	Approved	[26]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[27]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[28]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[29]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[30]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[31]

Drug(s) Affected By Solute carrier family 22 member 7 (SLC22A7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[32]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[33]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[34]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[35]
Allopurinol	DMLPAOB	Gout	FA25	Approved	[35]
Bumetanide	DMRV7H0	Congestive heart failure	BD10	Approved	[35]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[35]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[35]
Tetracycline	DMZA017	Acne vulgaris	ED80	Approved	[35]
Ranitidine	DM0GUSX	Gastric ulcer	DA60	Approved	[36]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)	TT3PQ2Y	PYRD_PLAF7	Inhibitor	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Regulatory-associated protein of mTOR (RPTOR)	OT4TQZ9F	RPTOR_HUMAN	Post-Translational Modifications	[3]
Ribosomal protein S6 kinase beta-1 (RPS6KB1)	OTAELNGX	KS6B1_HUMAN	Post-Translational Modifications	[3]
Solute carrier family 22 member 7 (SLC22A7)	OTKTNH1W	S22A7_HUMAN	Regulation of Drug Effects	[4]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4690).
• [2] Structure-activity relationships of pyrimidines as dihydroorotate dehydrogenase inhibitors. Biochem Pharmacol. 1988 Oct 15;37(20):3807-16.
• [3] Proliferating effect of orotic acid through mTORC1 activation mediated by negative regulation of AMPK in SK-Hep1 hepatocellular carcinoma cells. J Toxicol Sci. 2012;37(4):813-21. doi: 10.2131/jts.37.813.
• [4] Benzoic acid and specific 2-oxo acids activate hepatic efflux of glutamate at OAT2. Biochim Biophys Acta. 2013 Feb;1828(2):491-8. doi: 10.1016/j.bbamem.2012.08.026. Epub 2012 Sep 7.
• [5] The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
• [6] Identification and characterization of potential new therapeutic targets in inflammatory and autoimmune diseases. Eur J Biochem. 1999 Dec;266(3):1184-91.
• [7] Expression and characterization of E. coli-produced soluble, functional human dihydroorotate dehydrogenase: a potential target for immunosuppression. J Mol Microbiol Biotechnol. 1999 Aug;1(1):183-8.
• [8] Inhibitor binding in a class 2 dihydroorotate dehydrogenase causes variations in the membrane-associated N-terminal domain. Protein Sci. 2004 Apr;13(4):1031-42.
• [9] Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid. Chem Biol Interact. 2000 Jan 3;124(1):61-76.
• [10] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [11] Antimalarial activity of orotate analogs that inhibit dihydroorotase and dihydroorotate dehydrogenase. Biochem Pharmacol. 1992 Mar 17;43(6):1295-301.
• [12] Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone. Blood. 2004 Apr 15;103(8):3138-47. doi: 10.1182/blood-2003-05-1543. Epub 2003 Dec 24.
• [13] Antidepressant drug sertraline modulates AMPK-MTOR signaling-mediated autophagy via targeting mitochondrial VDAC1 protein. Autophagy. 2021 Oct;17(10):2783-2799. doi: 10.1080/15548627.2020.1841953. Epub 2020 Nov 9.
• [14] EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells. PLoS One. 2011;6(6):e18691. doi: 10.1371/journal.pone.0018691. Epub 2011 Jun 2.
• [15] Oxidative stress induces parallel autophagy and mitochondria dysfunction in human glioma U251 cells. Toxicol Sci. 2009 Aug;110(2):376-88. doi: 10.1093/toxsci/kfp101. Epub 2009 May 18.
• [16] Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin Cancer Res. 2012 Aug 15;18(16):4345-55. doi: 10.1158/1078-0432.CCR-11-3227. Epub 2012 Jun 25.
• [17] Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
• [18] SU5416 inhibited VEGF and HIF-1alpha expression through the PI3K/AKT/p70S6K1 signaling pathway. Biochem Biophys Res Commun. 2004 Nov 12;324(2):471-80. doi: 10.1016/j.bbrc.2004.09.082.
• [19] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [20] D-glucosamine down-regulates HIF-1alpha through inhibition of protein translation in DU145 prostate cancer cells. Biochem Biophys Res Commun. 2009 Apr 24;382(1):96-101. doi: 10.1016/j.bbrc.2009.02.129. Epub 2009 Feb 28.
• [21] Arsenic trioxide inhibits translation of mRNA of bcr-abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells. Cancer Res. 2003 Nov 15;63(22):7950-8.
• [22] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [23] Nuclear and Mitochondrial DNA Methylation Patterns Induced by Valproic Acid in Human Hepatocytes. Chem Res Toxicol. 2017 Oct 16;30(10):1847-1854. doi: 10.1021/acs.chemrestox.7b00171. Epub 2017 Sep 13.
• [24] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [25] The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
• [26] Pioglitazone, a PPAR agonist, attenuates PDGF-induced vascular smooth muscle cell proliferation through AMPK-dependent and AMPK-independent inhibition of mTOR/p70S6K and ERK signaling. Biochem Pharmacol. 2016 Feb 1;101:54-70. doi: 10.1016/j.bcp.2015.11.026. Epub 2015 Nov 28.
• [27] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [28] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [29] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [30] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [31] The human myometrium differentially expresses mTOR signalling components before and during pregnancy: evidence for regulation by progesterone. J Steroid Biochem Mol Biol. 2014 Jan;139:166-72. doi: 10.1016/j.jsbmb.2013.02.017. Epub 2013 Mar 26.
• [32] Interactions of human organic anion transporters and human organic cation transporters with nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther. 2002 Nov;303(2):534-9.
• [33] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [34] Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23. doi: 10.1007/s00204-013-1169-3. Epub 2013 Nov 30.
• [35] Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol. 2005 May;57(5):573-8.
• [36] A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.